Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT.CN) - Breaking News
February 27, 2018

Abattis Enters Into Definitive Agreement To Acquire Gabriola Green Farms

Vancouver, British Columbia --February 27, 2018 -- Abattis Bioceuticals Corp.  (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to announce that it has entered into a definitive agreement (the “Definitive Agreement”) to acquire (the “Acquisition”) a 90% ownership interest in Gabriola Green Farms Inc. (“Gabriola”).

Gabriola is a privately held British Columbia company that has applied for a license to produce (an “LP”) under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) on Gabriola Island, one of the gulf islands located in the Strait of Georgia off the coast of British Columbia. Gabriola Island has a consistent temperature and humidity level, which makes it well suited to greenhouse growing.

“This is one of the most significant steps our Company has taken towards becoming a full service cannabis company,” stated Rob Abenante, Abattis President and CEO. “After successfully obtaining a license through Gabriola, we intend to not only cultivate marijuana, but more importantly sell extracted cannabis products, which will complete our full downstream service offerings”.

The Definitive Agreement comes following a series of rapid acquisitions, capital raises, investments and joint-ventures for the Company, which include the acquisition of a cash flowing vaporizer company, investment into a cutting-edge Blockchain technology and cryptocurrency and several collaborations with respected organizations, including the University of British Columbia.

Pursuant to the Definitive Agreement, in exchange for a 90% ownership interest in Gabriola, Abattis will issue an aggregate of 59,760,956 common shares of the Company (each, a “Share”), at a deemed price of $0.3765 per Share, and pay an aggregate of $2.5 million in cash to the shareholders of Gabriola, with the exception of CannaNUMUS Blockchain Inc. (“CannaNUMUS”), a company in which Abattis owns a 49% stake, which will retain its 10% ownership stake in Gabriola. In addition, Abattis will make milestone-based payments (the “Milestone Payments”) to such shareholders of Gabriola of (i) $5 million upon Gabriola’s receipt of a cultivation license under the ACMPR and (ii) $5 million upon Gabriola’s receipt of a sales license under the ACMPR. The Milestone Payments will be satisfied through the issuance of Shares. Closing of the Acquisition is subject to, among other things, completion of due diligence by Abattis and the receipt of any required consents, including that of the Canadian Securities Exchange.

In connection with the Acquisition, Abattis has also secured (i) a right of first refusal on the remaining 10% ownership interest in Gabriola from CannaNUMUS and (ii) an option to acquire the lands on which Gabriola’s operations are conducted for $7 million until February 27, 2023 from an unrelated third-party.
“Our acquisition of Gabriola will round out our product offerings and complement our existing offerings in the cannabis products, technologies and services space. With its production facility located on ideal Gabriola Island, Gabriola has the potential to become a significant producer upon receipt of an LP,” stated Rob Abenante. “With our powerful cash position and liquidity, as well as our experience across various domains in the cannabis space, we are well positioned to support Gabriola’s expansion”.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

"Rob Abenante"
Robert Abenante, President & CEO
For more information, please visit the Company's website at: www.abattis.com  or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", “intends”, "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: the Acquisition, including the consideration payable thereunder; Gabriola’s application for an LP; Abattis’s intention, upon Gabriola’s receipt of an LP, to not only cultivate marijuana, but also sell extracted cannabis products, and that such activities will complete Abattis’s full downstream service offerings; the Acquisition rounding out Abattis’s product offerings and complementing its existing offerings across the cannabis technologies and services space; that Gabriola has the potential to become a significant producer upon receipt of an LP; and the fact that, with its powerful cash position and liquidity, as well as its experience across various domains in the cannabis space, Abattis is well positioned to support Gabriola’s expansion. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that the Acquisition will not complete under the terms as contemplated or at all; that Gabriola’s application for an LP will be unsuccessful; that, upon Gabriola’s receipt of an LP, Abattis will not cultivate marijuana or sell extracted cannabis products, or that such activities will not complete Abattis’s full downstream service offerings; that the Acquisition will not round out Abattis’s product offerings or not complement its existing offerings across the cannabis technologies and services space; that Gabriola will not become a significant producer upon receipt of an LP; that, with its powerful cash position and liquidity, as well as its experience across various domains in the cannabis space, Abattis will not be well positioned to support Gabriola’s expansion; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company's Management's Discussion and Analysis, available under the Company's profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.  NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Abattis Bioceuticals Corp.

Abattis Announces CannaNUMUS Achievement of Second MilestonePress Release

Vancouver, British Columbia --February 20, 2018 -- Abattis Bioceuticals Corp.  (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to announce that CannaNUMUS Blockchain Inc. ("CannaNUMUS"), a company in which Abattis has a 49% ownership interest, has entered into an agreement to acquire (the “Investment”) a 10% stake in Gabriola Green Farms ("Gabriola") for $2.5 million. Through the Investment, Gabriola will participate in CannaNUMUS's blockchain portfolio of cannabis companies.

Gabriola is a privately held British Columbia company that has applied for a licence to produce under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on Gabriola Island, one of the gulf islands located in the Strait of Georgia off the coast of British Columbia. Gabriola Island has a consistent temperature and humidity level, which makes it well suited to greenhouse growing. Gabriola's current facility has a production capacity of approximately 2,000 kilograms.

Through the agreement with Gabriola, CannaNUMUS has satisfied the second milestone under the Investment Agreement dated January 31, 2018 between Abattis and CannaNUMUS.

"We are very impressed with the progress and execution at CannaNUMUS," stated Rob Abenante, President and CEO of Abattis. "We believe the collaboration between the two companies will be extremely beneficial for both entities."

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

"Rob Abenante"
Robert Abenante, President & CEO

For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

Certain information set out in this news release constitutes forward-looking information. Forward-looking statements (often, but not always, identified by the use of words such as "expect", "may", "could", "anticipate" or "will" and similar expressions) may describe expectations, opinions or guidance that are not statements of fact and which may be based upon information provided by third parties. Forward-looking statements are based upon the opinions, expectations and estimates of management of the Company as at the date the statements are made and are subject to a variety of known and unknown risks and uncertainties and other factors that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. Those factors include, but are not limited to statements regarding the expected benefit to CannaNUMUS and Abattis of their collaboration, risks, uncertainties and other factors that are beyond the control of the Company, risks associated with the cannabis industry in general, rules and regulations relating to the cannabis industry, operational risks associated with development and production operations, delays or changes in plans and unanticipated costs and expenses, among others. In light of the risks and uncertainties associated with forward-looking statements, readers are cautioned not to place undue reliance upon forward-looking information. In particular, there is no assurance that CannaNUMUS and Abattis will benefit from their collaboration as expected or at all. Although the Company believes that the expectations reflected in the forward-looking statements set out in this news release are reasonable, it can give no assurance that such expectations will prove to have been correct. The forward-looking statements of the Company contained in this news release are expressly qualified, in their entirety, by this cautionary statement. Except as required by law, we do not undertake to update any forward-looking statement contained in this news release.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Abattis Bioceuticals Corp.

Abattis awarded a Mitacs grant for R&D of nanoemulsified cannabinoid-rich hemp oil in conjunction with food scientists from the University of British Columbia

Vancouver, British Columbia --February 12, 2018 -- Abattis Bioceuticals Corp.  (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to announce the sponsorship of a research study in partnership with Mitacs to explore the development of nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil. The research and development work will be led by scientists from Abattis and the Faculty of Land and Food Systems at the University of British Columbia (“UBC”).

Mitacs is a national, not-for-profit organization that has designed and delivered research and training programs in Canada for 18 years working with 60 universities, thousands of companies, and both federal and provincial governments.

In addition to the R&D work on cannabinoid-rich THC-free hemp extracts, scientist from Abattis and UBC’s Faculty of Land and Food Systems will work to create delivery platforms with increased stability and bioavailability.

“Abattis is very pleased to begin working with premiere scientists from UBC, and in the University’s first-class cell-culture research facility,” said Rob Abenante, President and CEO of Abattis.

Mr. Abenante added: “Our partnership will focus on developing nanoparticle-based delivery platforms since nanoparticulation allow more efficient and faster absorption of active compounds such as cannabinoids and terpenes, reducing the typical losses associated with gut absorption. This new development is part of our overall strategy to provide high-end extracts to our manufacturing partners and to support the development of unique finished products.”

"Our research will help develop stable encapsulated hemp-oil formulations for delivering the medicinal ingredients of cannabis orally, but without the harmful effects of smoking. Stable hemp extracts, with tailored profiles of cannabinoids and terpenes, could be used for targeted treatment of patients and help them lead a healthy lifestyle," said Dr. Anubhav Pratap Singh, Assistant Professor, Food Nutrition and Health Program, Faculty of Land and Food Systems, UBC.

The University of British Columbia’s Faculty of Land and Food Systems has world-class research laboratories with modern analytical instrumentation. UBC consistently ranks among the Top 40 universities in the world, and among the Top 20 public universities in the world.

"Securing this partnership provides additional support to our Research and Development strategy to prepare a new class of cannabis and hemp finished products with high bioavailability, stability and shelf-life. This technology will become a core driver for a future line of formulations to be used under white-label, and in-house finished products," said Dr. David Galvez, Senior Science Advisor of Abattis.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.

ON BEHALF OF THE BOARD,
ABATTIS BIOCEUTICALS CORP,

“Rob Abenante"
Robert Abenante, President & CEO

For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 336-0881 or at news@abattis.com.

Certain information set out in this news release constitutes forward-looking information. Forward-looking statements (often, but not always, identified by the use of words such as "expect", "may", "could", "anticipate" or "will" and similar expressions) may describe expectations, opinions or guidance that are not statements of fact and which may be based upon information provided by third parties. Forward-looking statements are based upon the opinions, expectations and estimates of management of the Company as at the date the statements are made and are subject to a variety of known and unknown risks and uncertainties and other factors that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. Those factors include, but are not limited to statements regarding the expected benefit to CannaNUMUS and Abattis of their collaboration, risks, uncertainties and other factors that are beyond the control of the Company, risks associated with the cannabis industry in general, rules and regulations relating to the cannabis industry, operational risks associated with development and production operations, delays or changes in plans and unanticipated costs and expenses, among others. In light of the risks and uncertainties associated with forward-looking statements, readers are cautioned not to place undue reliance upon forward-looking information. In particular, there is no assurance that CannaNUMUS and Abattis will benefit from their collaboration as expected or at all. Although the Company believes that the expectations reflected in the forward-looking statements set out in this news release are reasonable, it can give no assurance that such expectations will prove to have been correct. The forward-looking statements of the Company contained in this news release are expressly qualified, in their entirety, by this cautionary statement. Except as required by law, we do not undertake to update any forward-looking statement contained in this news release.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Abattis Bioceuticals Corp.

Abattis Completes Investment in CannaNUMUS Blockchain and Announces CannaNUMUS’s Achievement of a Significant Milestone

Vancouver, British Columbia --February 08, 2018 -- Abattis Bioceuticals Corp.  (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") announces that, further to its news release dated February 1, 2018, it has completed its acquisition of a 49% stake in CannaNUMUS Blockchain Inc. (“CannaNUMUS”), pursuant to the investment agreement dated January 31, 2018 between the Company and CannaNUMUS (the “Investment Agreement”).

The Company is also pleased to announce that CannaNUMUS has achieved the first milestone (the “Milestone”) under the Investment Agreement by entering into an agreement with Active Health Products Ltd (“Active Health”).

“We are excited to see such immediate progress on our investment in CannaNUMUS,” stated Rob Abenante, President and CEO of Abattis. “We believe this is just beginning of many more lucrative agreements and synergies for CannaNUMUS with LPs and also Licensed Dealers,” added Mr. Abenante.

Abattis believes that its investment in CannaNUMUS will appreciate significantly in value as CannaNUMUS gets closer to an ICO and signs agreements with Licensed Producers (“LPs”) and late stage LP applicants.

Active Health, located in Duncan, BC, is the second cannabis cultivation project for its founder and CEO, Jim Money. Mr. Money, recently developed and sold Broken Coast Cannabis Inc. (“Broken Coast”), also located on Vancouver Island, for $230 million to Aphria Inc. Broken Coast is now successfully operating as a licensed producer.

Pursuant to Active Health’s agreement with CannaNUMUS, CannaNUMUS will invest into Active Health and, in exchange, Active Health will participate as one of CannaNUMUS’s blockchain portfolio companies. More specifically, Active Health will use a fixed percentage of its quarterly revenues to buy CannaNUMUS tokens on the open market and subsequently burn them. The effect of the “buy and burn” will be similar to that when a company repurchases its own stock, and will function as method of providing liquidity to the market for CannaNUMUS tokens. Token burning will also act as a low-friction method of returning value to token holders.

CannaNUMUS’s innovative approach is expected to leverage blockchain technology in a way that brings market participants closer to the companies that they wish to support. Costly and laborious fund-administration procedures that are typical of many investment funds will replaced by a new, transparent approach to funding. When paired with well managed companies like Active Health, there will be significant potential for changing the way that investors are involved in markets.

“With our model, you take well managed companies, pair them with the investment oversight in CannaNUMUS, and support those relationships with transparent and secure technology,” stated Simran Gill, CEO of CannaNUMUS. “At the end of the day, there’s more left on the table for investors,” added Mr. Gill.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

“Rob Abenante"
Robert Abenante, President & CEO
For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com
For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

Certain information set out in this news release constitutes forward-looking information. Forward-looking statements (often, but not always, identified by the use of words such as "expect", "may", "could", "anticipate" or "will" and similar expressions) may describe expectations, opinions or guidance that are not statements of fact and which may be based upon information provided by third parties. Forward-looking statements are based upon the opinions, expectations and estimates of management of the Company as at the date the statements are made and are subject to a variety of known and unknown risks and uncertainties and other factors that could cause actual events or outcomes to differ materially from those anticipated or implied by such forward-looking statements. Those factors include, but are not limited to statements regarding the expected benefit to CannaNUMUS and Abattis of their collaboration, risks, uncertainties and other factors that are beyond the control of the Company, risks associated with the cannabis industry in general, rules and regulations relating to the cannabis industry, operational risks associated with development and production operations, delays or changes in plans and unanticipated costs and expenses, among others. In light of the risks and uncertainties associated with forward-looking statements, readers are cautioned not to place undue reliance upon forward-looking information. In particular, there is no assurance that CannaNUMUS and Abattis will benefit from their collaboration as expected or at all. Although the Company believes that the expectations reflected in the forward-looking statements set out in this news release are reasonable, it can give no assurance that such expectations will prove to have been correct. The forward-looking statements of the Company contained in this news release are expressly qualified, in their entirety, by this cautionary statement. Except as required by law, we do not undertake to update any forward-looking statement contained in this news release.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Abattis Bioceuticals Corp.

-------------------------------------------------------------------
About Abattis Bioceuticals Corp.:

Abattis is Research & Development. Extraction & Formulation.Testing & Analysis. Sales & Distribution.

Abattis Bioceuticals has positioned itself to be a leading service provider in the cannabis industry.

Integrated solutions for cannabis based and natural formulations, extracts and product development from concept to market delivery.

Federally Licensed Testing Lab
Northern Vine Labs holds a controlled substance dealers license from health Canada.

Proprietary Extraction Technology
Abattis has exclusive distribution rights to sell and service an industrial scale and cost effective extraction technology.

Custom Product Formulations
Northern Vine Labs' product formulation specialists can create and consult on custom developed products.

Regulatory & Consulting
Abattis provides full service regulatory consulting services.

Sales, Distribution, Marketing & Branding
Vergence has extensive product development expertise and established international sales & distribution channels.

Our Brands

Northern Vine Labs™
Through its subsidiary, Northern Vine Canada Inc., Abattis owns one of a very few Health Canada approved testing labs with a Controlled Substance License to formulate, test and develop cannabis derivatives and related products through formulation and patented technologies.

Northern Vine Labs provides:

- On-site testing of legal cannabis and cannabis derivatives
- Product research and formulation development
- Proprietary extraction partnerships

Vergence Naturals™
Vergence is a bioceutical branding, marketing and sales company focused on health products to penetrate the fast-growing market for safe and effective natural products that meet unmet wellness needs. Its key products are geared towards natural cannabinoid enhanced goods.


Vergence provides:

- Turnkey branding and marketing for products
- Natural Product Number (NPN) granted products
- Direct product distribution via online sales and established brick and mortar networks

Abattis Bioceuticals offers a wide range of solutions for companies operating in the medical marijuana and cannabis natural health sectors. We have developed over 150 custom formulations and continue to break new ground in testing standards, produced development and providing exclusive cannabinoid extracts and formulations for specific health and wellness issues.

We Make Strategic Investments In Key Areas of the Industry
Abattis is a specialized life sciences and biotechnology company based in British Columbia, Canada. Through our wholly owned subsidiaries, we are engaged in aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry.

Our portfolio of investments in strategic areas of the industry includes advanced research operations, laboratory facilities and staff, as well as vertically integrated product, brand and marketing operations.

Northern Vine Labs™
A subsidiary of Abattis, Northern Vine Labs™ is poised to become a premier analytical testing laboratory, and research and development partner to the mass of companies emerging in the legal cannabis space in Canada.

The ability to work legally with cannabis is a rare designation and remains a highly specialized and coveted position within the research sector.

Northern Vine Lab's™ Controlled Substance License provides the company with the unique ability to offer proprietary methods and services to current licensed producers within Canada’s existing Federal regulatory structure. It also gives Northern Vine Labs'™ customers, including Abattis subsidiaries or affiliates, the ability to formulate and develop new products containing cannabinoid ingredients in anticipation of future widened legal market distribution.

Vergence Naturals

Launched by Abattis in 2016, Vergence Naturals is an integrated product company focused on innovative health offerings to penetrate the fast growing market for natural, safe and effective solutions to two of society’s unresolved and ubiquitous health issues: pain caused by inflammation and mental ailments effected by modern lifestyles.

Vergence Naturals is guided by skilled nutraceutical marketing and brand specialists with years of success in the traditional nutraceutical and formulations business. They are applying their previous successes to the new, burgeoning CDB and cannabinoid formulations market for natural products.

Lab Services
Abattis Bioceuticals offers a complete array of Health-Canada licensed services for the cannabis industry.

Lab and Research Services
Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian cannabis market.

Formulations
Our laboratories follow strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions.

Abattis Bioceuticals is perfectly positioned to provide a full suite of downstream services to these products and the thousands of products that will come online as recreational and medicinal legalization laws progress in Canada and Internationally.

SOURCE: https://abattis.com/

Disclaimer